Compare ARK Genomic Revolution ETF (ARKG) vs Matson Inc (MATX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Matson Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Matson Inc trades at $204.77 (market cap $6.20B). The key difference: Matson Inc pays a 0.74% dividend while ARK Genomic Revolution ETF pays none, and Matson Inc is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | MATX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $206.03 |
52-Week Low | $23.09 | $88.05 |
Market Cap | — | $6.20B |
Enterprise Value | — | $6.79B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Matson (MATX) trades at $204.77, down 0.61% today but near recent highs, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.85 exceeding expectations. Fundamentals show solid profitability with a 12.92% net income margin and a reasonable P/E of 15.19. Recent developments include a dividend increase to $0.38 per share and progress on new vessel construction.
The outlook remains positive given consistent earnings outperformance and strategic fleet investments, though risks include exposure to Pacific trade volatility and moderating profit margins. Analyst consensus is bullish with 64% buy ratings, supporting potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
